Barinthus Biotherapeutics plc (NASDAQ:BRNS – Get Free Report) saw a large growth in short interest during the month of July. As of July 15th, there was short interest totalling 29,800 shares, a growth of 223.9% from the June 30th total of 9,200 shares. Currently, 0.1% of the shares of the stock are short sold. Based on an average daily volume of 24,300 shares, the days-to-cover ratio is currently 1.2 days.
Barinthus Biotherapeutics Trading Down 6.2 %
Barinthus Biotherapeutics stock traded down $0.09 during midday trading on Friday, reaching $1.37. The stock had a trading volume of 24,533 shares, compared to its average volume of 26,262. Barinthus Biotherapeutics has a 12 month low of $1.21 and a 12 month high of $5.10. The firm’s 50-day moving average price is $1.69 and its 200 day moving average price is $2.34.
Barinthus Biotherapeutics (NASDAQ:BRNS – Get Free Report) last issued its earnings results on Monday, May 13th. The company reported ($0.40) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.64) by $0.24. As a group, research analysts anticipate that Barinthus Biotherapeutics will post -1.9 EPS for the current year.
Institutional Investors Weigh In On Barinthus Biotherapeutics
Wall Street Analysts Forecast Growth
A number of equities research analysts have recently commented on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $8.00 price objective on shares of Barinthus Biotherapeutics in a research note on Friday, June 7th. William Blair reissued an “outperform” rating on shares of Barinthus Biotherapeutics in a research note on Thursday, June 13th. Finally, Barclays reduced their price objective on shares of Barinthus Biotherapeutics from $7.00 to $3.00 and set an “overweight” rating for the company in a research report on Thursday, June 13th.
View Our Latest Research Report on Barinthus Biotherapeutics
About Barinthus Biotherapeutics
Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer.
Recommended Stories
- Five stocks we like better than Barinthus Biotherapeutics
- Insider Trading – What You Need to Know
- Why Call Options Volume for These 2 Stocks Spiked Together
- How to Effectively Use the MarketBeat Ratings Screener
- MarketBeat Week in Review – 7/22 – 7/26
- NYSE Stocks Give Investors a Variety of Quality Options
- 3M Surprises and Rebound Accelerates: It Isn’t Too Late To Get In
Receive News & Ratings for Barinthus Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Barinthus Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.